Payment overview · 2025
General Payments
$676.72
34 reported records · 12 companies
Healthcare provider profile · identity verified
Isaac Sosa, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · UVALDE, TX · NPI 1275558611
Verified facts
What the public records show
CMS Open Payments records show Isaac Sosa, M.D. received $676.72 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.56 | 22.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.19 | 21.6% | 8 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $93.22 | 13.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.66 | 12.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.07 | 5.6% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.53 | 5.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.36 | 4.0% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.05 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.23 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.15 | 2.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.47 | 2.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.23 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $676.72 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $153.56 | 6 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $93.22 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.66 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54.75 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $34.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.36 | 2 | 2025 |
Source payment records
|
|||||
| Venxxiva Normalized: venxxiva |
Drug | Cycle Pharmaceuticals Inc | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $9.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 174 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
174 | 33 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 646 | 179 |
| Losartan Potassium | Losartan Potassium | 625 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 161 |
| Gabapentin | Gabapentin | 578 | 142 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 495 | 162 |
| Metformin Hcl | Metformin Hcl | 434 | 136 |
| Lisinopril | Lisinopril | 402 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 96 |
| Omeprazole | Omeprazole | 336 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 100 |
| Furosemide | Furosemide | 297 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 72 |
| Potassium Chloride | Potassium Chloride | 252 | 71 |
| Dexamethasone | Dexamethasone | 209 | 154 |
| Tramadol Hcl | Tramadol Hcl | 209 | 63 |
| Glipizide | Glipizide | 200 | 54 |
| Donepezil Hcl | Donepezil Hcl | 180 | 54 |
| Simvastatin | Simvastatin | 180 | 49 |
| Alprazolam | Alprazolam | 174 | 35 |
| Ozempic | Semaglutide | 174 | 33 |
| Eliquis | Apixaban | 170 | 32 |
| Sertraline Hcl | Sertraline Hcl | 167 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 42 |
| Alendronate Sodium | Alendronate Sodium | 144 | 48 |
| Lorazepam | Lorazepam | 144 | 25 |
| Carvedilol | Carvedilol | 140 | 35 |
| Jardiance | Empagliflozin | 139 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 43 |
| Trazodone Hcl | Trazodone Hcl | 139 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 57 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 136 | 111 |
| Mounjaro | Tirzepatide | 135 | 18 |
| Pregabalin | Pregabalin | 135 | 37 |
| Nifedipine Er | Nifedipine | 131 | 36 |
| Cephalexin | Cephalexin | 125 | 99 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 36 |
| Montelukast Sodium | Montelukast Sodium | 118 | 35 |
| Finasteride | Finasteride | 115 | 38 |
| Azithromycin | Azithromycin | 111 | 98 |
| Glimepiride | Glimepiride | 108 | 33 |
| Celecoxib | Celecoxib | 106 | 36 |
| Levofloxacin | Levofloxacin | 105 | 78 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 24 |
| Enalapril Maleate | Enalapril Maleate | 98 | 22 |
| Ibuprofen | Ibuprofen | 96 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 23 |
| Clonazepam | Clonazepam | 93 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 28 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 93 | 17 |
| Meclizine Hcl | Meclizine Hcl | 92 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 28 |
| Allopurinol | Allopurinol | 85 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 69 |
| Fenofibrate | Fenofibrate Nanocrystallized | 84 | 24 |
| Memantine Hcl | Memantine Hcl | 80 | 20 |
| Meloxicam | Meloxicam | 79 | 38 |
| Methocarbamol | Methocarbamol | 76 | 26 |
| Famotidine | Famotidine | 75 | 22 |
| Januvia | Sitagliptin Phosphate | 75 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 20 |
| Cefdinir | Cefdinir | 71 | 60 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 33 |
| Ezetimibe | Ezetimibe | 69 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 14 |
| Torsemide | Torsemide | 68 | 22 |
| Mirtazapine | Mirtazapine | 66 | 15 |
| Prednisone | Prednisone | 66 | 44 |
| Levemir Flexpen | Insulin Detemir | 64 | 19 |
| Colchicine | Colchicine | 63 | 21 |
| Metformin Hcl Er | Metformin Hcl | 63 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 34 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 19 |
| Spironolactone | Spironolactone | 62 | 19 |
| Myrbetriq | Mirabegron | 61 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 19 |
| Farxiga | Dapagliflozin Propanediol | 58 | 17 |
| Fluconazole | Fluconazole | 57 | 40 |
| Tradjenta | Linagliptin | 57 | 14 |
| Bupropion Xl | Bupropion Hcl | 56 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 44 |
| Valsartan | Valsartan | 49 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 30 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | 18 |
| Acyclovir | Acyclovir | 40 | 16 |
| Glipizide Er | Glipizide | 40 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 16 |
| Primidone | Primidone | 37 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 36 | 15 |
| Amoxicillin | Amoxicillin | 35 | 29 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Naproxen | Naproxen | 35 | 15 |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 33 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 33 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Bumetanide | Bumetanide | 31 | 14 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 26 |
| Sucralfate | Sucralfate | 31 | 16 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 30 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 19 |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 19 |
| Metronidazole | Metronidazole | 24 | 23 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 13 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $676.72 · 34 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, BREZTRI, EVENITY, FARXIGA, GEMTESA, Kerendia, MOUNJARO, OTEZLA, Ozempic, PROLIA, PURIFIED CORTROPHIN GEL, QUTENZA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, Venxxiva, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error